替泊沙林和美洛昔康在猫临床应用中的评估。
Evaluation of the clinical use of tepoxalin and meloxicam in cats.
作者信息
Charlton Anna N, Benito Javier, Simpson Wendy, Freire Mila, Lascelles B Duncan X
机构信息
Comparative Pain Research Laboratory, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, USA.
出版信息
J Feline Med Surg. 2013 Aug;15(8):678-90. doi: 10.1177/1098612X12473994. Epub 2013 Jan 24.
Medical records where tepoxalin (Zubrin) or meloxicam (Metacam) were prescribed in cats were reviewed and data extracted. Comparisons were performed for exploring changes between pre- and post-non-steroidal anti-inflammatory drug course laboratory tests. Seventy-nine medical records fit the inclusion criteria (n = 57 and n = 22, tepoxalin and meloxicam, respectively). The median dosages administered were 13 and 0.029 mg/kg(/)day (tepoxalin and meloxicam, respectively). Median prescription durations were 11 (2-919) and 93 (4-1814) days for tepoxalin and meloxicam, respectively. Suspected adverse events were reported for tepoxalin (9%, 5/57 cats) and meloxicam (18%, 4/22 cats) a median of 774 and 448 days, respectively, after the prescription started. For cats prescribed meloxicam, there were several statistically significant changes for serum biochemistry and hematology parameters, but median values were within normal limits. These valuable clinical data suggest that tepoxalin and meloxicam are well tolerated in the clinical setting at the doses prescribed in this study.
回顾了给猫开替泊沙林（祖布林）或美洛昔康（美达佳）的病历并提取数据。进行比较以探索非甾体抗炎药疗程前后实验室检查的变化。79份病历符合纳入标准（替泊沙林和美洛昔康分别为n = 57和n = 22）。给药的中位剂量分别为13和0.029毫克/千克/天（替泊沙林和美洛昔康）。替泊沙林和美洛昔康的中位处方持续时间分别为11（2 - 919）天和93（4 - 1814）天。替泊沙林（9%，5/57只猫）和美洛昔康（18%，4/22只猫）分别在处方开始后中位774天和448天报告了疑似不良事件。对于开了美洛昔康的猫，血清生化和血液学参数有几个具有统计学意义的变化，但中位值在正常范围内。这些有价值的临床数据表明，在本研究规定的剂量下，替泊沙林和美洛昔康在临床环境中耐受性良好。
Zotero 插件